Patents by Inventor Keliang Liu
Keliang Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9750841Abstract: A medical adhesive with good biodegradable performance capable of undergoing crosslinking copolymerization, comprising a mono-alpha-cyanoacrylate and a bis-alpha-cyanoacrylic acid diol ester monomer molecule. The olefinic bonds in the mono-alpha-cyanoacrylate structure are polymerized in the presence of infinitesimal anions to form a solid 3D high polymer; the 3D high polymer is provided with degradation sites on the web-like backbone chain, with clear degradation path and absorbable degradation products. The medical adhesive can be used for wound adhesive, large area wound hemostasia, and visceral and soft tissue wound closure.Type: GrantFiled: October 31, 2012Date of Patent: September 5, 2017Assignees: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A., CHENGDU YIPING MEDICAL SCIENCE & TECHNOLOGY CO. LTDInventors: Keliang Liu, Liang Xu, Qingsong Zhang, Dazhen Cai, Qingbin Meng
-
Patent number: 9464128Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogs, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.Type: GrantFiled: June 4, 2008Date of Patent: October 11, 2016Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A.Inventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
-
Patent number: 9260534Abstract: Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aap]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.Type: GrantFiled: August 11, 2011Date of Patent: February 16, 2016Assignees: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China, Chengdu Yiping Medical Science & Technology Co., Ltd.Inventors: Keliang Liu, Yuanjun Liang, Xiaoyu Xu, Sicheng Li
-
Publication number: 20140369952Abstract: A medical adhesive with good biodegradable performance capable of undergoing crosslinking copolymerization, comprising a mono-alpha-cyanoacrylate and a bis-alpha-cyanoacrylic acid diol ester monomer molecule. The olefinic bonds in the mono-alpha-cyanoacrylate structure are polymerized in the presence of infinitesimal anions to form a solid 3D high polymer; the 3D high polymer is provided with degradation sites on the web-like backbone chain, with clear degradation path and absorbable degradation products. The medical adhesive can be used for wound adhesive, large area wound hemostasia, and visceral and soft tissue wound closure.Type: ApplicationFiled: October 31, 2012Publication date: December 18, 2014Inventors: Keliang Liu, Liang Xu, Qingsong Zhang, Dazhen Cai, Qingbin Meng
-
Publication number: 20130310310Abstract: Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aap]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.Type: ApplicationFiled: August 11, 2011Publication date: November 21, 2013Applicants: Chengdu Yiping Medical Science & Technology Co., Ltd., Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Keliang Liu, Yuanjun Liang, Xiaoyu Xu, Sicheng Li
-
Patent number: 8080522Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.Type: GrantFiled: November 11, 2006Date of Patent: December 20, 2011Assignee: Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.L.A., ChinaInventors: Keliang Liu, Jiankun Qie, Jinbo Ma, Jianquan Zheng, Sijian Dong, Wenxia Zhou, Chunhui Qi
-
Publication number: 20110306633Abstract: The present invention provides a selective M4 receptor antagonist, levorotatory demethylated phencynonate or its nontoxic pharmaceutically acceptable salt, a pharmaceutical composition comprising this compound, and a use thereof in the manufacture of a medicament for the treatment of motion dysfunction, such as, tremor, rigor and the like caused by Parkinson's disease (PD).Type: ApplicationFiled: November 7, 2007Publication date: December 15, 2011Applicant: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A.CHINAInventors: Bohua Zhong, Jianquan Zheng, Liyun Wang, He Liu, Lanfu Chen, Keliang Liu
-
Publication number: 20110091420Abstract: Disclosed are an injectable sustained-release pharmaceutical formulation and a process for preparing the same. In some embodiments, the formulation comprises an active ingredient in a therapeutically effective amount, an amphipathic molecule, an organic acid and/or a salt thereof which is hardly soluble in water, and an oily solvent. The injectable sustained-release pharmaceutical formulation provides a good sustained-release effect for various active ingredients, in particular peptides, proteins, nucleic acids and saccharides.Type: ApplicationFiled: March 20, 2009Publication date: April 21, 2011Applicants: Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, People Liberation Ar, Chengdu Yiping Pharmaceutical Science Development Co., Ltd.Inventors: Keliang Liu, Dongqin Quan, Yuanjun Liang, Qingbin Meng, Chenhong Wang, Junlin He, Qiyan Jia, Sicheng Li
-
Publication number: 20100227815Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.Type: ApplicationFiled: June 4, 2008Publication date: September 9, 2010Applicant: Institute of Pharmacology and Toxicology Academy Of Military Medical ScienceInventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
-
Publication number: 20090221487Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.Type: ApplicationFiled: November 11, 2006Publication date: September 3, 2009Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Keliang Liu, Jiankun Qie, Jinbo Ma, Jianquan Zheng, Sijian Dong, Sijian Dong, Wenxia Zhou, Chunhui Qi
-
Patent number: 6953780Abstract: The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.Type: GrantFiled: June 21, 2001Date of Patent: October 11, 2005Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A.Inventors: Keliang Liu, Wensheng Yu, Yuanjun Liang, Hai Wang, Yufen Zhao, Zhenkai Ding
-
Publication number: 20040038906Abstract: The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.Type: ApplicationFiled: May 29, 2003Publication date: February 26, 2004Inventors: Keliang Liu, Wensheng Yu, Yuanjun Liang, Hai Wang, Yufen Zhao, Zhenkai Ding